Optimi Health Corp. (CSE: OPTI, Nasdaq: OPTH) announced on October 20, 2026, that it has completed a production batch of MDMA finished drug product intended to supply three separate programs across Canada, Israel, and Australia. The capsules were manufactured at the company's GMP-certified facility in Princeton, British Columbia, under a Health Canada Drug Establishment Licence. The milestone is significant for investors as it positions Optimi at the intersection of regulated psychedelic medicine across multiple international jurisdictions simultaneously.
Key Points
- Optimi Health Corp. (CSE: OPTI, Nasdaq: OPTH, FSE: 8BN) is a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products.
- The completed MDMA batch is intended to supply a proposed Canadian Phase 3 PTSD clinical trial, a MAPS-partnered trial in Israel, and a commercial export to Australia before end of 2026.
- The proposed Canadian Phase 3 trial aims to enrol up to 100 veterans and frontline workers across multiple sites, with a trial start expected in 2027.
- Investors may be watching progress on Health Canada authorisation, the Australian shipment timeline, and any enrolment updates for the Phase 3 trial.
Canadian Phase 3 Trial Targets Veterans and Frontline Workers with Two-Session MDMA Therapy
The proposed Canadian Phase 3 trial, which has received Health Canada authorisation to proceed, is designed to evaluate the efficacy and safety of MDMA-assisted therapy in up to 100 participants — specifically veterans and current or former frontline workers. Participants are expected to receive two supervised sessions combining synthetic MDMA hydrochloride and psychotherapy, spaced several weeks apart, with follow-up evaluations thereafter. The primary efficacy endpoint will be change in the Clinician-Administered PTSD Scale (CAPS-5), a standard clinician-rated instrument for assessing PTSD severity. The trial is expected to begin in 2027. The safety and efficacy of MDMA-assisted therapy to treat PTSD remains under investigation in Canada, and Optimi's MDMA products have not received market authorisation from Health Canada.
Australian Commercial Supply Continues as Export Shipment Planned Before End of 2026
Optimi has received Australian import permits for MDMA and states that its next commercial shipment to Australia is planned before the end of 2026, supplying clinics and pharmacies through Optimi Australia. In Australia, clinicians are authorised to prescribe MDMA capsules to PTSD patients under the Therapeutic Goods Administration's Authorised Prescriber Scheme, with reimbursement available through several public and private payers. The company states that more than 750 clinicians have completed Mind Medicine Australia's Certificate in Psychedelic-Assisted Therapies, and that it is not aware of any reported serious adverse events among patients since commercial supply commenced in 2024.
MAPS Israel Partnership Adds Third Destination for the Completed Production Batch
The completed production batch also supports a clinical trial in Israel conducted in partnership with the Multidisciplinary Association for Psychedelic Studies (MAPS), focused on PTSD treatment. As previously announced by the company on November 26, 2025, Optimi supplies MDMA capsules for MAPS Israel's Healing October 7th project, a clinical trial that has received formal approval from the Israeli Ministry of Health. The release states that the current batch is expected to meet supply requirements across all three programs, reflecting the company's stated capacity to serve regulated clinical and commercial programs internationally from its British Columbia manufacturing facility.





Please wait processing your request...